Calpain-1 inhibitors for selective treatment of rheumatoid arthritis: what is the future?

Miller, David James, Adams, Sarah Elizabeth, Hallett, Maurice Bartlett ORCID: https://orcid.org/0000-0001-8197-834X and Allemann, Rudolf Konrad ORCID: https://orcid.org/0000-0002-1323-8830 2013. Calpain-1 inhibitors for selective treatment of rheumatoid arthritis: what is the future? Future Medicinal Chemistry 5 (17) , pp. 2057-2074. 10.4155/fmc.13.172

Full text not available from this repository.

Abstract

Effective small-molecule treatment of inflammatory diseases remains an unmet need in medicine. Current treatments are either limited in effectiveness or invasive. The latest biologics prevent influx of inflammatory cells to damaged tissue. Calpain-1 is a calcium-activated cysteine protease that plays an important role in neutrophil motility. It is, therefore, a potential target for intervention in inflammatory disease. Many inhibitors of calpains have been developed but most are unselective and so unsuitable for drug use. However, recent series of α-mercaptoacrylate inhibitors target regulatory domains of calpain-1 and are much more specific. These compounds are effective in impairing the cell spreading mechanism of neutrophils in vitro and raise the possibility of treating rheumatoid arthritis with a pill; however, challenges still remain. Improved bioavailability is needed and solution of their precise mode of action should prompt the development of specific calpain-1 screens for novel classes of inhibitors.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Chemistry Medicine
Subjects:	Q Science > QD Chemistry R Medicine > RM Therapeutics. Pharmacology
Publisher:	Future Science Ltd
ISSN:	1756-8919
Last Modified:	25 Oct 2022 10:14
URI:	https://orca.cardiff.ac.uk/id/eprint/61500

Citation Data

Cited 7 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item